{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-073735","form_type":"8-K","ticker":"ADVB","cik":"0001941029","company_name":"Advanced Biomed Inc.","filed_at":"2026-06-30T20:34:32+00:00","discovered_at":"2026-06-30T20:35:00.459453+00:00","generated_at":"2026-06-30T20:35:14.068057+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Advanced Biomed sells Taiwan subsidiary for $490k; retains AI operations","bullets":["Sale of 100% of Taiwan subsidiary for $490k cash to buyer Miaozhu Zhao.","Taiwan subsidiary conducts biomedical R&D including A+PerfusC integrated perfusion 3D cell culture platform.","Company will continue AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited.","Closing expected within three months from June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-073735","json":"https://secwatch.observer/filing/0001213900-26-073735.json","markdown":"https://secwatch.observer/filing/0001213900-26-073735.md","text":"https://secwatch.observer/filing/0001213900-26-073735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026073735/0001213900-26-073735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026073735/ea0296529-8k_advanced.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T20:35:14.068057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}